Tesaro, a MA based biotech, announced it has successfully reached its Phase III endpoint of progression-free survival (PFS) among all of the 490 patients with recurrent ovarian cancer included in the study. The drug niraparib, a PARP inhibitor, proved effective in a double-blind, placebo controlled, international study among women with the BRCA mutation and for women without the mutation as well as those with HRD-positive and HRD-negative tumors. This is great news for the 239,000 women diagnosed with ovarian cancer each year, especially considering the difficulty in catching this disease in its early stages. All in the form of a single, daily, oral dose. Take that, cancer.